Skip Navigation

Annals of Oncology 2007 18(4):613; doi:10.1093/annonc/mdm118
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Venlafaxine versus clonidine for hot flashes in breast cancer patients
 
Aproximately two thirds of postmenopausal breast cancer patients report hot flashes, which can significantly impair quality of life, especially when estrogens are contraindicated or rejected. Clonidine is widely used as a non-estrogenic treatment for hot flashes in breast cancer patients and does decrease hot flashes to a moderate degree but it is associated with several toxicities. Venlafaxine is an antidepressant selective serotonin-norepinephrine reuptake inhibitor (SNRI), and . . . [Full Text of this Article]


   Gefitinib and irinotecan for fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer
 

   Response assessment in lymphoma patients using FDG-PET/CT
 

   Chinese herbal medicine as complimentary therapy for reduction of chemotherapy-induced toxicity
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study
S Loibl, K Schwedler, G von Minckwitz, R Strohmeier, KM Mehta, and M Kaufmann
Ann Oncol 2007 18: 689-693. [Abstract] [Full Text]  

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study
I Chau, D Cunningham, T Hickish, A Massey, L Higgins, R Osborne, N Botwood, and A Swaisland
Ann Oncol 2007 18: 730-737. [Abstract] [Full Text]  

Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?
K Strobel, NG Schaefer, C Renner, P Veit-Haibach, D Husarik, AY Koma, and TF Hany
Ann Oncol 2007 18: 658-664. [Abstract] [Full Text]  

A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity
TSK Mok, W Yeo, PJ Johnson, P Hui, WM Ho, KC Lam, M Xu, K Chak, A Chan, H Wong, F Mo, and B Zee
Ann Oncol 2007 18: 768-774. [Abstract] [Full Text]